Sebi warns Dabur India over delayed USFDA warning letter disclosure
In short
Sebi has warned Dabur India for delaying the disclosure of a USFDA warning letter.
The regulator said repeated violations could lead to enforcement action under its rules. This raises compliance concerns for Dabur India.
What the reporting says
Sebi cautioned Dabur India over a delay in disclosing a USFDA warning letter. The market regulator said repeated violations could lead to enforcement action under Sebi rules. The warning highlights compliance risk for the company after the delayed disclosure.
Why it matters
Sebi cautioned Dabur India over delayed disclosure of a USFDA warning letter. The regulator said repeated violations could attract enforcement action under Sebi rules. The development raises regulatory and compliance concerns for Dabur India, with the warning focused on disclosure timing rather than a broader market issue.